Sinopharm Vaccine, SARS-CoV-2 breakthrough infections and Hemoglobinopathies

Main Article Content

Rujittika Mungmunpuntipantip
a:1:{s:5:"en_US";s:14:"medical center";}

Viroj Wiwanitkit

Keywords

Downloads

Download data is not yet available.


Abstract 325
PDF Downloads 294
HTML Downloads 144

References

1. Karimi M, Zarei T, Haghpanah S, Azarkeivan A, Naderi M, Matin S, Bazrafshan A, Zahedi Z, Shirkavand A, Pishdad P, De Sanctis V. Efficacy and Safety of Sinopharm Vaccine for SARS-CoV-2 and breakthrough infections in Iranian Patients with Hemoglobinopathies: A Preliminary Report. Mediterr J Hematol Infect Dis. 2022 Mar 1;14(1):e2022026. doi: 10.4084/MJHID.2022.026. eCollection 2022.
2. Fucharoen S, Weatherall DJ. The hemoglobin E thalassemias. Cold Spring Harb Perspect Med. 2012 Aug 1;2(8):a011734.
3. Jantarabenjakul W, Chantasrisawad N, Puthanakit T, Wacharapluesadee S, Hirankarn N, Ruenjaiman V, Paitoonpong L, Suwanpimolkul G, Torvorapanit P, Pradit R, Sophonphan J, Putcharoen O. Short-term immune response after inactivated SARS-CoV-2 (CoronaVac®, Sinovac) and ChAdOx1 nCoV-19 (Vaxzevria®, Oxford-AstraZeneca) vaccinations in health care workers. Asian Pac J Allergy Immunol. 2021 Oct 31. doi: 10.12932/AP-250721-1197. Online ahead of print.
4. Kittikraisak W, Hunsawong T, Punjasamanvong S, Wongrapee T, Suttha P, Piyaraj P, Leepiyasakulchai C, Tanathitikorn C, Yoocharoen P, Jones AR, Mongkolsirichaikul D, Westercamp M, Azziz-Baumgartner E, Mott JA, Chottanapund S. Anti-SARS-CoV-2 IgG antibody levels among Thai healthcare providers receiving homologous and heterologous COVID-19 vaccination regimens. Influenza Other Respir Viruses. 2022 Feb 24. doi: 10.1111/irv.12975. Online ahead of print.

Article Sidebar

PDF HTML
Published
Jun 29, 2022
DOI https://doi.org/10.4084/MJHID.2022.060

Article Details

How to Cite

Mungmunpuntipantip, R. and Wiwanitkit, V. (2022) “Sinopharm Vaccine, SARS-CoV-2 breakthrough infections and Hemoglobinopathies”, Mediterranean Journal of Hematology and Infectious Diseases, 14(1), p. e2022060. doi: 10.4084/MJHID.2022.060.
Issue
Vol. 14 No. 1 (2022): Review Articles, Original Article, Scientific Letter, Case Reports Letter to the Editor
Section
Letters to the Editor
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Transfer of Copyright and Permission to Reproduce Parts of Published Papers. Authors will grant copyright of their articles to the Institute of Hematology, Catholic University, Rome . No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.